ArQule Aktie [WKN: 903396 / ISIN: US04269E1073]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Historisch	Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu ArQule Inc.

10.12.19		Top Gainers: THOR Acquired, FTSV Up On Magrolimab Data, Investors Believe FATE (RTTNews)
09.12.19		Had You Invested In ArQule (ARQL) In June,... (RTTNews)
09.12.19		Merck To Acquire ArQule For $20/share In Cash - Quick Facts (RTTNews)
09.12.19		ArQule Announces Final Phase 1 Clinical Data for Its Reversible BTK Inhibitor, ARQ 531, at the American Society of Hematology 2019 Annual Meeting (Businesswire)
25.11.19		ArQule to Present Clinical Data for its Reversible BTK Inhibitor, ARQ 531, at the American Society of Hematology 2019 Annual Meeting (Businesswire)
30.10.19		EARNINGS SUMMARY: Details of ArQule Inc. Q3 Earnings Report (RTTNews)
30.10.19		ArQule Reports Third Quarter 2019 Financial Results (Businesswire)
29.10.19		ArQule Presents Recent Data on ARQ 751 at the 2019 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (Businesswire)
16.10.19		ArQule to Report Third Quarter 2019 Financial Results on October 30, 2019 (Businesswire)
16.10.19		ArQule Announces Presentations on ARQ 751 at the 2019 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (Businesswire)
08.10.19		ArQule to Present Preclinical Data on Miransertib for the Treatment of Vascular Malformations at the 2019 American Society of Human Genetics (ASHG) Annual Meeting (Businesswire)
26.09.19		ArQule to Present at the 2019 Cantor Global Healthcare Conference on October 3, 2019 (Businesswire)
17.09.19		ArQule to Participate in the Oppenheimer Fall Summit Focused on Specialty Pharma and Rare Disease Companies on September 24, 2019 (Businesswire)
10.09.19		5 Top Losers In Healthcare Sector (NTRP, AKRO, SAVA...) (RTTNews)
28.08.19		ArQule to Participate in Citi’s 14th Annual Biotech Conference on September 4, 2019 (Businesswire)
07.08.19		EARNINGS SUMMARY: Details of ArQule Inc. Q2 Earnings Report (RTTNews)
07.08.19		ArQule Reports Second Quarter 2019 Financial Results (Businesswire)
05.08.19		ArQule to Participate in the BTIG Biotechnology Conference on Monday, August 12, 2019 (Businesswire)
01.08.19		ArQule to Present at the SVB Leerink Spotlight Series: Rare & Genetic Diseases on August 8, 2019 (Businesswire)
24.07.19		ArQule to Report Second Quarter 2019 Financial Results on August 7, 2019 (Businesswire)
27.06.19		ArQule Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares (Businesswire)
25.06.19		ArQule Announces Pricing of $90 Million Public Offering of Common Stock (Businesswire)
24.06.19		ArQule Announces Commencement of Proposed Public Offering of Common Stock (Businesswire)
18.06.19		ArQule to Present at the BMO Prescriptions for Success Healthcare Conference on June 25, 2019 (Businesswire)
10.06.19		ArQule Announces Oral Presentation for its Pan-AKT Inhibitor, Miransertib, at the 2019 European Society of Human Genetics (ESHG) Conference (Businesswire)
07.06.19		ArQule to Present Clinical Data for its BTK Inhibitor, ARQ 531, at the 24th Congress of the European Hematology Association (EHA) (Businesswire)
30.05.19		ArQule to Present at the Jefferies 2019 Healthcare Conference on June 6, 2019 (Businesswire)
15.05.19		ArQule to Present at the 20th Annual B. Riley FBR Institutional Investor Conference on May 22, 2019 (Businesswire)
14.05.19		ArQule to Present at the 2019 RBC Capital Markets Global Healthcare Conference on May 21, 2019 (Businesswire)
08.05.19		ArQule to Present at the Bank of America Merrill Lynch 2019 Health Care Conference on May 15, 2019 (Businesswire)
01.05.19		EARNINGS SUMMARY: Details of ArQule Inc. Q1 Earnings Report (RTTNews)
01.05.19		ArQule Reports First Quarter 2019 Financial Results (Businesswire)
17.04.19		ArQule to Report First Quarter 2019 Financial Results on May 1, 2019 (Businesswire)
02.04.19		ArQule to Present at 18th Annual Needham Healthcare Conference on April 9, 2019 (Businesswire)
15.03.19		ArQule Announces Management Team Changes (Businesswire)
13.03.19		ArQule to Present at Oppenheimer’s 29th Annual Healthcare Conference on March 20, 2019 (Businesswire)
11.03.19		ArQule to Participate in the 31st Annual ROTH Conference on March 17-19, 2019 (Businesswire)
08.03.19		9 Top Gainers In Healthcare Sector (BPTH, ARQL, SEEL…) (RTTNews)
07.03.19		ArQule Reports Fourth Quarter and Full Year 2018 Financial Results (Businesswire)
25.02.19		ArQule Announces Publication of Clinical Data with Miransertib in Proteus Syndrome (Businesswire)
21.02.19		ArQule to Report Fourth Quarter and Full Year 2018 Financial Results on March 7, 2019 (Businesswire)
21.02.19		ArQule to Present at the 8th Annual Leerink Partners Global Healthcare Conference on February 28, 2019 (Businesswire)
24.01.19		Basilea Announces Collaboration to Study Derazantinib and Atezolizumab (Tecentriq®) in Urothelial Cancer (Businesswire)
09.01.19		Basilea Announces Positive Interim Results from Registrational Phase 2 Study with Oncology Drug Candidate Derazantinib in Intrahepatic Cholangiocarcinoma (iCCA) (Businesswire)
19.12.18		ArQule Added to the NASDAQ Biotechnology Index (Businesswire)
03.12.18		ArQule Announces Clinical Data from Ongoing Phase 1 Study of Reversible BTK Inhibitor, ARQ 531, in Patients with Relapsed/Refractory Hematologic Malignancies at the 2018 ASH Annual Meeting (Businesswire)
01.12.18		ArQule to Present Clinical Data for its BTK Inhibitor, ARQ 531, at the 2018 American Society of Hematology (ASH) Annual Meeting (Businesswire)
29.11.18		ArQule to Host Analyst Call Highlighting Clinical Progress from Ongoing Phase 1 Study of Reversible BTK Inhibitor, ARQ 531, in Patients with Relapsed/Refractory Hematologic Malignancies (Businesswire)
19.11.18		ArQule to Present Clinical Data for its BTK Inhibitor, ARQ 531, at the 2018 American Society of Hematology (ASH) Annual Meeting (Businesswire)
16.11.18		ArQule Presents Clinical and Preclinical Data for ARQ 751 at the 30th EORTC/AACR/NCI Symposium (Businesswire)

1 | Weiter

Newssuche

Meistgelesene Nachrichten

voestalpine-Aktie mit Verlusten: Stabile Erdgasversorgung trotz möglicher Unterbrechungen aus Russland

NVIDIA-Aktie profitiert von starkem Plus bei Umsatz und Gewinn

SBO-Aktie rutscht deutlich ab: Schoeller-Bleckmann verzeichnet deutlichen Gewinneinbruch nach drei Quartalen

UNIQA steigert Ergebnis trotz Unwetterschäden - Trennung von Beteiligungen in Albanien, Kosovo und Nordmazedonien - Aktie profitiert

Neuer Rekord: Bitcoin klettert über 99.000 Dollar

Kryptorally setzt sich fort: Bitcoin, Dogecoin, Ethereum & Co. am Donnerstagmittag

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2024 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	23.11.2024 23:04
Kaufwert:	EUR
	Hinzufügen Speichern